Phenotypes associated with this allele

• Allele Symbol: U2af1^tm1.1Hev
• Allele Name: targeted mutation 1.1, Harold E Varmus
• Allele ID: MGI:6202047
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Runx1^tm3Spe/Runx1^tm3Spe U2af1^tm1.1Hev/U2af1^+ Tg(Mx1-cre)1Cgn/0	involves: 129S4/SvJae * 129S6/SvEvTac * BALB/c * C57BL/6 * CBA/J	MGI:6273496
cn2	Tg(Mx1-cre)1Cgn/0 U2af1^tm1.1Hev/U2af1^+	involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6J * CBA/J	MGI:6273483

Genotype
MGI:6273496

cn1

• Allelic Composition: Runx1^tm3Spe/Runx1^tm3Spe; U2af1^tm1.1Hev/U2af1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S4/SvJae * 129S6/SvEvTac * BALB/c * C57BL/6 * CBA/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal blood cell morphology ( J:267082 )

• poly (IC) treated mice develop multilineage cytopenia

abnormal myeloid cell morphology ( J:267082 )

• mice develop low-level myeloid dysplasia after poly (IC) treatment

thrombocytopenia ( J:267082 )

• mice develop thrombocytopenia after poly (IC) treatment

increased myeloid cell number ( J:267082 )

• mice exhibit an increased percentage of myeloid cells and increased myeloid colony formation after poly (IC) treatment

abnormal erythroid lineage cell morphology ( J:267082 )

• mice develop low-level erythroid dysplasia after poly (IC) treatment

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:267082 )

• one mouse treated with ENU after poly (IC) treatment developed acute myeloid leukemia

• mice treated with ENU after poly (IC) treatment exhibit increased percentages of myeloid cells in the peripheral blood, enlarged spleen, and extramedullary hematopoiesis, occasional low-grade dysplasia in the erythroid and neutrophil lineages indicating the development of myeloproliferative neoplasm

mortality/aging

mortality/aging ( J:267082 )

N • poly (IC) treated mice have a normal life span and do not develop frank leukemia within 1.5 years after poly (IC) treatment

increased susceptibility to induced morbidity/mortality ( J:267082 )

• mice treated with ENU after poly (IC) treatment die prematurely with myeloid pathology

neoplasm

increased incidence of tumors by chemical induction ( J:267082 )

• one mouse treated with ENU after poly (IC) treatment developed acute myeloid leukemia

• mice treated with ENU after poly (IC) treatment exhibit increased percentages of myeloid cells in the peripheral blood, enlarged spleen, and extramedullary hematopoiesis, occasional low-grade dysplasia in the erythroid and neutrophil lineages indicating the development of myeloproliferative neoplasm

Genotype
MGI:6273483

cn2

• Allelic Composition: Tg(Mx1-cre)1Cgn/0; U2af1^tm1.1Hev/U2af1⁺
• Genetic Background: involves: 129S6/SvEvTac * BALB/c * C57BL/6 * C57BL/6J * CBA/J

hematopoietic system

macrocytic anemia ( J:267082 )

• mice exhibit a mild reduction in red blood cell count and increase in mean red blood cell volume after poly (IC) treatment, indicating macrocytic anemia

abnormal bone marrow cell morphology/development ( J:267082 )

• binucleated erythroid cells and hypo-segmented neutrophils are seen in the bone marrow cells occasionally in poly (IC) treated mice

• megakaryocytes occasionally form clusters in poly (IC) treated mice

• these dysplastic features affect less than 1% of bone marrow cells and are not seen in the peripheral blood

decreased erythrocyte cell number ( J:267082 )

• mice show a mild reduction in red blood cell count after poly (IC) treatment

• however, platelet numbers are normal, bone marrow cellularity and spleen size are normal after poly (IC) treatment

decreased hematocrit ( J:267082 )

• mice show a mild reduction in hematocrit after poly (IC) treatment

decreased hemoglobin content ( J:267082 )

• mice show a mild reduction in hemoglobin concentration after poly (IC) treatment

increased mean corpuscular volume ( J:267082 )

• mice show a mild increase in mean corpuscular volume after poly (IC) treatment

decreased leukocyte cell number ( J:267082 )

• poly (IC) treated mice show a nearly 50% reduction in numbers of white blood cells, with decreases in all major lineages and the most marked reduction in B220+ B cells

decreased hematopoietic stem cell number ( J:267082 )

• the hematopoietic stem cell- and progenitor-enriched LSK cells (Lin-Sca-1+C-Kit+) are decreased in the bone marrow at 36 weeks after poly (IC) treatment; decrease in the LSK cells is due to the reduction of short-term and long-term HSCs (CD48-CD150- and CD48-CD150+, respectively) but not the multipotent progenitors in the bone marrow

• however, no differences are seen in the percentages of Lin- cells and MPs after poly (IC) treatment

immune system

decreased leukocyte cell number ( J:267082 )

• poly (IC) treated mice show a nearly 50% reduction in numbers of white blood cells, with decreases in all major lineages and the most marked reduction in B220+ B cells

mortality/aging

mortality/aging ( J:267082 )

N • poly (IC) treated mice exhibit a normal life span

neoplasm

neoplasm ( J:267082 )

N • mice do not develop leukemia following poly (IC) treatment